Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls

American Journal of Neuroradiology

Volumn 33, Issue 9, 2012, Pages 1763-1770

  Mong, S ^a   Ellingson, B M ^a   Nghiemphu, P L ^a   Kim, H J ^a   Mirsadraei, L ^a   Lai, A ^a   Yong, W ^a   Zaw, T M ^a   Cloughesy, T F ^a   Pope, W B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; LESIONS AND DEFECTS; MALE; NEUROIMAGING; OVERALL SURVIVAL; RESTRICTED DIFFUSION LESION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867799455     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3053     Document Type: Article

References (21)

1. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20
2. Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Curr TreatOptions Neurol 2010;12:321-33
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733- 40
4. Ellingson BM, Cloughesy TF, Lai A, et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:401-09
5. Ellingson BM, Cloughesy TF, Lai A, et al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol2011;13:1151-61
6. Ellingson BM, Cloughesy TF, Lai A, et al. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011;105:91-101
7. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging2010;31:538-48
8. Sadeghi N, D'Haene N, Decaestecker C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol2008;29:476-82 (Pubitemid 351424060)
9. Luthra G, Parihar A, Nath K, et al. Comparative evaluation of fungal, tubercular, and pyogenic brain abscesses with conventional and diffusion MR imaging and proton MR spectroscopy. AJNR Am J Neuroradiol2007;28:1332-38 (Pubitemid 47309668)
10. Somford DM, Marks MP, Thijs VN, et al. Association of early CT abnormalities, infarct size, and apparent diffusion coefficient reduction in acute ischemic stroke. AJNR Am J Neuroradiol 2004;25:933-38 (Pubitemid 38765869)
11. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol2010;28:e91-93
12. Rieger J, Bahr O, Muller K, et al. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49-56
13. Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011;32:1301-06
14. Hakyemez B, Erdogan C, Yildirim N, et al. Glioblastoma multiforme with atypical diffusion-weighted MR findings. Br J Radiol 2005;78:989-92 (Pubitemid 41684025)
15. Chiang IC, Hsieh TJ, Chiu ML, et al. Distinction between pyogenic brain abscess and necrotic brain tumour using 3-Tesla MR spectroscopy, diffusion and perfusion imaging. Br J Radiol 2009;82:813-20
16. Reese TG, Heid O, Weisskoff RM, et al. Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn ResonMed 2003;49:177-82 (Pubitemid 36042349)
17. Bedekar D, Jensen T, Schmainda KM. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magn Reson Med 2010;64:907-13
18. Ledezma CJ, Chen W, Sai V, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 2009;71:242-48
19. Rogers LR, Gutierrez J, Scarpace L, et al. Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis. J Neurooncol 2011;101:25-32
20. Yamasaki F, Kurisu K, Satoh K, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005;235:985-99
21. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-37